Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27839176 | 0.78 | LDHA (0.45) | LDHAALDH1A1LMNAALOX15APEX1 | |
| SCHEMBL7430015 | 0.76 | ACACB (0.46) | ALDH1A1LMNAALOX15APEX1MAPK1 | |
| SCHEMBL22278814 | 0.74 | CA12 (0.44) | ALDH1A1LMNAALOX15APEX1MAPK1 | |
| SCHEMBL29226421 | 0.73 | ALDH1A1 (0.46) | LDHAALDH1A1LMNAALOX15APEX1 | |
| SCHEMBL8937536 | 0.73 | LDHA (0.47) | LDHAALDH1A1LMNAALOX15APEX1 | |
| SCHEMBL29226417 | 0.73 | ALDH1A1 (0.46) | LDHAALDH1A1LMNAALOX15APEX1 | |
| SCHEMBL10794450 | 0.73 | LDHA (0.47) | LDHAALDH1A1LMNAALOX15APEX1 | |
| SCHEMBL18902445 | 0.72 | KIF11 (0.47) | ALDH1A1LMNAKIF11KMT2A | |
| SCHEMBL2795435 | 0.72 | CYP2C9 (0.55) | ALDH1A1LMNAALOX15APEX1MAPK1 | |
| SCHEMBL5144776 | 0.72 | CA1 (0.52) | LDHAALDH1A1LMNAALOX15APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1435962-A4 | TREATMENT OF TYPE I DIABETES | CELL PATHWAYS INC (US) | 2009-04-15 | — | — | EP | disclosed |
| EP-1435940-A4 | TREATMENT OF SCLERODERMA | CELL PATHWAYS INC (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1435961-A4 | TREATMENT FOR LUPUS ERYTHEMATOSUS | CELL PATHWAYS INC (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1435962-A2 | TREATMENT OF TYPE I DIABETES | Cell Pathways, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1435940-A1 | TREATMENT OF SCLERODERMA | Cell Pathways, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1435782-A1 | TREATMENT FOR CYSTIC FIBROSIS | Cell Pathways, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1435961-A2 | TREATMENT FOR LUPUS ERYTHEMATOSUS | Cell Pathways, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030176316-A1 | Methods for treatment of rheumatoid arthritis | OSI PHARMACEUTICALS, INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003017999-A1 | TREATMENT OF SCLERODERMA | CELL PATHWAYS, INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| WO-2003017765-A1 | TREATMENT FOR CYSTIC FIBROSIS | CELL PATHWAYS, INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| WO-2003017926-A2 | TREATMENT FOR LUPUS ERYTHEMATOSUS | CELL PATHWAYS, INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| WO-2003017925-A2 | TREATMENT OF TYPE I DIABETES | CELL PATHWAYS, INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| WO-2002067936-A1 | METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | CELL PATHWAYS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| EP-1044187-A1 | N-BENZYL-3-INDENYLACETAMIDES DERIVATIVES FOR TREATING NEOPLASIA | OSI Pharmaceuticals, Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999031065-A1 | N-BENZYL-3-INDENYLACETAMIDES DERIVATIVES FOR TREATING NEOPLASIA | CELL PATHWAYS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176316-A1 | Methods for treatment of rheumatoid arthritis | SSB, AADAC, NFKBIA | LDHA 1626/4885ALDH1A1 191/4885LMNA 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.